David E Geller

Summary

Affiliation: Alfred I. duPont Hospital for Children
Country: USA

Publications

  1. ncbi request reprint Respiratory care and cystic fibrosis
    David E Geller
    Aerosol Research Laboratory, Cystic Fibrosis Center, Biomedical Research, Nemours Children s Clinic, 496 S Delaney Avenue, Suite 406A, Orlando FL 32801, USA
    Respir Care 54:796-800. 2009
  2. doi request reprint Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis
    David E Geller
    Nemours Children s Clinic, Orlando, Florida 3280, USA
    Respir Med 105:S24-31. 2011
  3. ncbi request reprint Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
    David E Geller
    Nemours Children s Clinic, Division of Pulmonology, Orlando, FL 32806, USA
    Chest 122:219-26. 2002
  4. doi request reprint Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa
    David E Geller
    Nemours Children s Clinic, Orlando, FL 32801, USA
    Am J Respir Crit Care Med 183:1510-6. 2011
  5. pmc Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology
    David E Geller
    Aerosol Research Laboratory and Cystic Fibrosis Center, Nemours Children s Clinic, Orlando, Florida
    J Aerosol Med Pulm Drug Deliv 24:175-82. 2011
  6. pmc The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation
    David E Geller
    Nemours Children s Clinic Aerosol Research Lab, Orlando, Florida 32801, USA
    J Aerosol Med Pulm Drug Deliv 23:S55-9. 2010
  7. ncbi request reprint Aerosol antibiotics in cystic fibrosis
    David E Geller
    Aerosol Research Laboratory and Cystic Fibrosis Center, Nemours Children s Clinic, 496 S Delaney Avenue, Suite 406A, Orlando, FL 32801, USA
    Respir Care 54:658-70. 2009
  8. ncbi request reprint Clinical side effects during aerosol therapy: cutaneous and ocular effects
    David E Geller
    Nemours Children s Clinic, Orlando, Florida, USA
    J Aerosol Med 20:S100-8; discussion S109. 2007
  9. ncbi request reprint Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety
    David E Geller
    Nemours Children s Clinic, Orlando, Florida 32806, USA
    Pediatr Pulmonol 42:307-13. 2007
  10. ncbi request reprint New liquid aerosol generation devices: systems that force pressurized liquids through nozzles
    David E Geller
    Aerosol Research Laboratory and Cystic Fibrosis Center, The Nemours Children s Clinic, Orlando, FL 32806, USA
    Respir Care 47:1392-404; discussion 1404-5. 2002

Detail Information

Publications18

  1. ncbi request reprint Respiratory care and cystic fibrosis
    David E Geller
    Aerosol Research Laboratory, Cystic Fibrosis Center, Biomedical Research, Nemours Children s Clinic, 496 S Delaney Avenue, Suite 406A, Orlando FL 32801, USA
    Respir Care 54:796-800. 2009
    ..The May and June 2009 issues of the Journal reflect how diligently the participants worked to provide up-to-date reviews and lively discussions of these topics...
  2. doi request reprint Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis
    David E Geller
    Nemours Children s Clinic, Orlando, Florida 3280, USA
    Respir Med 105:S24-31. 2011
    ..Clinicians need to explore both technological and psychological strategies that will assist in the successful maintenance of treatment requirements...
  3. ncbi request reprint Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
    David E Geller
    Nemours Children s Clinic, Division of Pulmonology, Orlando, FL 32806, USA
    Chest 122:219-26. 2002
    ....
  4. doi request reprint Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa
    David E Geller
    Nemours Children s Clinic, Orlando, FL 32801, USA
    Am J Respir Crit Care Med 183:1510-6. 2011
    ..New treatment options for CF pulmonary infections are needed...
  5. pmc Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology
    David E Geller
    Aerosol Research Laboratory and Cystic Fibrosis Center, Nemours Children s Clinic, Orlando, Florida
    J Aerosol Med Pulm Drug Deliv 24:175-82. 2011
    ..The availability of more efficient and convenient treatment options may improve treatment compliance, and thereby therapeutic outcomes in CF...
  6. pmc The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation
    David E Geller
    Nemours Children s Clinic Aerosol Research Lab, Orlando, Florida 32801, USA
    J Aerosol Med Pulm Drug Deliv 23:S55-9. 2010
    ..The purposes of this in vitro study were to determine aerosol characteristics, device efficiency, and delivery time of AAT using the I-neb AAD System with TBM and TIM...
  7. ncbi request reprint Aerosol antibiotics in cystic fibrosis
    David E Geller
    Aerosol Research Laboratory and Cystic Fibrosis Center, Nemours Children s Clinic, 496 S Delaney Avenue, Suite 406A, Orlando, FL 32801, USA
    Respir Care 54:658-70. 2009
    ..Light, porous, dry-powder formulations are also in clinical trials to reduce delivery time. These new formulations and delivery systems promise to expand our armamentarium against microbes while reducing the time burden for patients...
  8. ncbi request reprint Clinical side effects during aerosol therapy: cutaneous and ocular effects
    David E Geller
    Nemours Children s Clinic, Orlando, Florida, USA
    J Aerosol Med 20:S100-8; discussion S109. 2007
    ..We do not know whether exposed children will have increased risks from ICS later in life. Therefore, it is wise to avoid face and eye deposition when possible, and to use the minimally effective dose...
  9. ncbi request reprint Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety
    David E Geller
    Nemours Children s Clinic, Orlando, Florida 32806, USA
    Pediatr Pulmonol 42:307-13. 2007
    ..The development of dry powder inhaled antibiotics may represent an important advance in the treatment of chronic lung infections...
  10. ncbi request reprint New liquid aerosol generation devices: systems that force pressurized liquids through nozzles
    David E Geller
    Aerosol Research Laboratory and Cystic Fibrosis Center, The Nemours Children s Clinic, Orlando, FL 32806, USA
    Respir Care 47:1392-404; discussion 1404-5. 2002
    ..These novel devices face competition from other technologies as well as financial and regulatory hurdles, but they both offer a marked improvement in the efficiency of pulmonary drug delivery...
  11. ncbi request reprint Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system
    David E Geller
    The Nemours Children s Clinic, 83 W Columbia St, Orlando, FL 32806 1101, USA
    Chest 123:28-36. 2003
    ..Second, we wanted to ascertain which AeroDose-delivered tobramycin dose is equivalent to the standard 300-mg dose administered with the PARI LC PLUS...
  12. ncbi request reprint Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis
    David Geller
    The Nemours Children s Clinic, Orlando, Florida 32806, USA
    J Aerosol Med 16:175-82. 2003
    ..This study demonstrated that bolus inhalation of rhDNase was feasible, reasonably well-tolerated, and associated with improvement in pulmonary function in this small group of cystic fibrosis subjects...
  13. ncbi request reprint Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler
    David E Geller
    The Nemours Children s Clinic, Orlando, Florida 32806, USA
    Respir Care 50:1313-21; discussion 1321-2. 2005
    ..Clinicians should also have a rudimentary understanding of aerosol principles in order to be able to teach appropriate use of aerosol devices to their patients...
  14. pmc Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects
    David E Geller
    Nemours Children s Clinic, 496 S Delaney Ave, Suite 406A, Orlando, Florida 32801, USA
    Antimicrob Agents Chemother 55:2636-40. 2011
    ..The pharmacokinetics, safety, and tolerability were similar for the two formulations. MP-376 240 mg (100 mg/ml) is being advanced into late-stage clinical development...
  15. ncbi request reprint New aerosol delivery devices for cystic fibrosis
    Kenneth C Kesser
    Aerosol Research Laboratory, Nemours Children s Clinic, 496 S Delaney Avenue, Suite 406A, Orlando FL 33801, USA
    Respir Care 54:754-67; discussion 767-8. 2009
    ..If successful, these systems will reduce the time burden and improve the clinical outcomes for the CF community...
  16. doi request reprint Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system
    Sarah A Perry
    Department of Anesthesiology and Critical Care Medicine, Nemours Alfred I duPont Hospital for Children, Wilmington, DE, USA
    Pediatr Crit Care Med 14:e250-6. 2013
    ..We investigated the in vitro inspired dose and particle size distribution of albuterol delivered by a vibrating mesh nebulizer through the Vapotherm (Stevensville, MD) humidified high-flow nasal cannula system...
  17. ncbi request reprint Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis
    Beth L Laube
    Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland 21287 2533, USA
    Respir Care 50:1438-44. 2005
    ..We hypothesized that aerosol distribution in the lungs of patients with cystic fibrosis changes with positive expiratory pressure (PEP)...
  18. ncbi request reprint Pulmonary exacerbations in cystic fibrosis
    Harvey R Rabin
    Foothills Medical Center and University of Calgary, Calgary, Alberta, Canada
    Pediatr Pulmonol 37:400-6. 2004
    ..The reproducibility of the model over time was confirmed by application to a subsequent set of data. This model has potential for use as an outcome measure in clinical trials, and to assist in treatment decisions for individual patients...